PRONOXIS

ProNoxis AB was founded in 2009 by LU Bioscience AB (LUBio), Karolinska Development AB, and Redoxis AB, as a Redoxis spin-off focusing on developing anti-inflammatory therapeutics targeting activation of the NADPH oxidase complex (NOX2)... ProNoxis focuses on the preclinical discovery of small-molecule drugs to treat chronic inflammation, autoimmunity and infections.

Also known as: Pronoxis AB

Primary location: Trollhättan